Belvisi, Maria G.
AstraZeneca Sweden,
Sweden
2025 Rank: 90116
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Respiratory System
SubField 2:
Pharmacology & Pharmacy
Rank in SubField 1: 530 out of 68788 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 90116 | 99600 |
| Total Cites | 781 | 842 |
| H-index | 11 | 11 |
| Hm-index | 4 | 5 |
| Number of Single Authored Papers | 9 | 9 |
| Total Cites to Single Authored Papers | 14 | 14 |
| Number of Single+First Authored Papers | 60 | 60 |
| Total Cites to Single+First Authored Papers | 71 | 74 |
| Number of Single+First+Last Authored Papers | 149 | 149 |
| Total Cites to Single+First+Last Authored Papers | 212 | 220 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 696 | 736 |
| Ratio of Total Citations to Distinct Citing Papers | 1.12 | 1.14 |
| Self-Citation Percentage |
7.24%
|
|
Belvisi, Maria G.
AstraZeneca,
Sweden
2024 Rank: 59489
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Respiratory System
SubField 2:
Pharmacology & Pharmacy
Rank in SubField 1: 379 out of 65702 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 59489 | 62837 |
| Total Cites | 857 | 929 |
| H-index | 13 | 14 |
| Hm-index | 5 | 5 |
| Number of Single Authored Papers | 9 | 9 |
| Total Cites to Single Authored Papers | 11 | 11 |
| Number of Single+First Authored Papers | 58 | 58 |
| Total Cites to Single+First Authored Papers | 87 | 92 |
| Number of Single+First+Last Authored Papers | 143 | 143 |
| Total Cites to Single+First+Last Authored Papers | 287 | 298 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 730 | 787 |
| Ratio of Total Citations to Distinct Citing Papers | 1.17 | 1.18 |
| Self-Citation Percentage |
7.75%
|
|
Belvisi, Maria G.
AstraZeneca Sweden,
Sweden
2023 Rank: 80722
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Respiratory System
SubField 2:
Pharmacology & Pharmacy
Rank in SubField 1: 556 out of 62427 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 80722 | 80987 |
| Total Cites | 715 | 803 |
| H-index | 13 | 13 |
| Hm-index | 5 | 5 |
| Number of Single Authored Papers | 9 | 9 |
| Total Cites to Single Authored Papers | 11 | 11 |
| Number of Single+First Authored Papers | 58 | 58 |
| Total Cites to Single+First Authored Papers | 62 | 70 |
| Number of Single+First+Last Authored Papers | 147 | 147 |
| Total Cites to Single+First+Last Authored Papers | 230 | 249 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 634 | 694 |
| Ratio of Total Citations to Distinct Citing Papers | 1.13 | 1.16 |
| Self-Citation Percentage |
10.96%
|
|
Belvisi, Maria G.
AstraZeneca Sweden,
Sweden
2022 Rank: 42496
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Respiratory System
SubField 2:
Pharmacology & Pharmacy
Rank in SubField 1: 317 out of 60663 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 42496 | 46940 |
| Total Cites | 784 | 840 |
| H-index | 14 | 14 |
| Hm-index | 6 | 6 |
| Number of Single Authored Papers | 9 | 9 |
| Total Cites to Single Authored Papers | 14 | 14 |
| Number of Single+First Authored Papers | 58 | 58 |
| Total Cites to Single+First Authored Papers | 109 | 121 |
| Number of Single+First+Last Authored Papers | 147 | 147 |
| Total Cites to Single+First+Last Authored Papers | 363 | 381 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 622 | 652 |
| Ratio of Total Citations to Distinct Citing Papers | 1.26 | 1.29 |
| Self-Citation Percentage |
6.67%
|
|
Belvisi, Maria G.
National Heart and Lung Institute,
United Kingdom
2021 Rank: 35706
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Respiratory System
Rank in SubField 1: 189 out of 131063 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 35706 | 38810 |
| Total Cites | 1221 | 1321 |
| H-index | 18 | 18 |
| Hm-index | 7 | 8 |
| Number of Single Authored Papers | 9 | 9 |
| Total Cites to Single Authored Papers | 23 | 23 |
| Number of Single+First Authored Papers | 58 | 58 |
| Total Cites to Single+First Authored Papers | 182 | 196 |
| Number of Single+First+Last Authored Papers | 146 | 146 |
| Total Cites to Single+First+Last Authored Papers | 583 | 612 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 921 | 971 |
| Ratio of Total Citations to Distinct Citing Papers | 1.33 | 1.36 |
| Self-Citation Percentage |
7.57%
|
|
Belvisi, Maria G.
AstraZeneca Sweden,
Sweden
2020 Rank: 41808
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Respiratory System
SubField 2:
Pharmacology & Pharmacy
Rank in SubField 1: 263 out of 52718 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 41808 | 45852 |
| Total Cites | 876 | 943 |
| H-index | 14 | 14 |
| Hm-index | 6 | 6 |
| Number of Single Authored Papers | 9 | 9 |
| Total Cites to Single Authored Papers | 19 | 19 |
| Number of Single+First Authored Papers | 58 | 58 |
| Total Cites to Single+First Authored Papers | 124 | 131 |
| Number of Single+First+Last Authored Papers | 144 | 144 |
| Total Cites to Single+First+Last Authored Papers | 385 | 403 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 698 | 739 |
| Ratio of Total Citations to Distinct Citing Papers | 1.26 | 1.28 |
| Self-Citation Percentage |
7.10%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.